Dicerna pens GalXC deal with Alexion; exercises option
Dicerna Pharmaceuticals Inc. granted Alexion Pharmaceuticals Inc. exclusive global rights to RNAi therapies for complement-mediated diseases. The projects will be discovered using Dicerna’s GalXC platform.
- Antisense, Oligonucleotides
- Large Molecule
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.